Predictive Role for Serum Aldo-Keto Reductase Family1 Member B10 for Early Detection of Hepatocellular Carcinoma in Egyptian Patients
DOI:
https://doi.org/10.3889/oamjms.2022.7149Keywords:
Alpha-fetoprotein, AKR1B10, Early detection, Hepatocellular carcinomaAbstract
Background: Most patients with hepatocellular carcinoma (HCC) are diagnosed at late stages despite of improvement screening programs and lack of effective diagnostic methods for cases with preclinical HCC leads to a low rate of early detection. Aldo-keto reductase family 1 member B10 (AKR1B10) is associated with several types of cancer. However, to our knowledge, the diagnostic significance of AKR1B10 measurement in early stage of HCC has poorly understood.
Aim
To evaluate the diagnostic performance of serum AKR1B10 in hepatitis C virus (HCV)-related liver disorders and its unique role in diagnosing HCC.
Methods
Serum AKR1B10 was detected by sandwich ELISA in 30 patients with HCV-related HCC, 30 patients with HCV related liver cirrhosis, and 20 healthy controls. Both Serum AKR1B10 and α-fetoprotein (AFP) levels were analyzed, evaluated and compared.
Results
Serum AKR1B10 was significantly elevated in patients with HCC compared with. The sensitivity (86.7.0%) and specificity (70%) for HCC diagnosis with AKR1B10 were high at a cutoff value of 0.945 ng/ml, while alpha fetoprotein had sensitivity 67% and specificity 88% in early detection of HCC among studied groups at cutoff point higher than 17.9. ng/ml. Furthermore, concurrent measurement of Alpha fetoprotein and AKR1B10 had increased sensitivity to 97.6% and specificity 100% in early detection of HCC among studied groups at cutoff point higher than ≥150 ng/ml. Furthermore, concurrent measurement of serum AKR1B10 and AFP significantly increased sensitivity and negative predictive value for HCC diagnosis.
Conclusions
we concluded in the current study that AKR1B10 has a unique role as a biomarker for early-stage HCV-related HCC. Compared with AFP alone, a combination of serum AKR1B10 and AFP had an increased the diagnostic performance in patients with HCC.
Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Wu S, Liu S, Liu Z, Huang J, Pu X, Li J, et al. Classification of circulating tumor cells by epithelial-mesenchymal transition markers. PLoS One. 2015;10(4):e0123976. http://doi.org/10.1371/journal.pone.0123976 PMid:25909322 DOI: https://doi.org/10.1371/journal.pone.0123976
Murata, A, Genda, T, Ichida, T, Amano, N, Sato, S, Tsuzura, H, et al. Pretreatment AKR1B10 expression predicts the risk of hepatocellular carcinoma development after hepatitis C virus eradication. World J Gastroenterol. 2016;22(33):7569-78. http://doi.org/10.3748/wjg.v22.i33.7569 PMid:27672277 DOI: https://doi.org/10.3748/wjg.v22.i33.7569
Han C, Gao L, Bai H, Dou X. Identification of a role for serum aldo keto reductase family 1 member B10 in early detection of hepatocellular carcinoma. Oncol Lett. 2018;16(6):7123-30. http://doi.org/10.3892/ol.2018.9547 PMid:30546447 DOI: https://doi.org/10.3892/ol.2018.9547
El Jabbour T, Lagana SM, Lee H. Update on hepatocellular carcinoma: Pathologists’ review. World J Gastroenterol. 2019;25(14):1653-65. http://doi.org/10.3748/wjg.v25.i14.1653 PMid:31011252 DOI: https://doi.org/10.3748/wjg.v25.i14.1653
Pham HH, Seong Y, Oh CW, Kim GD. The herbal medicine Cyperus amuricus inhibits proliferation of human hepatocellular carcinoma Hep3B cells by inducing apoptosis and arrest at the G0/G1 cell cycle phase. Int J Oncol. 2016;49(5):2046-54. http://doi.org/10.3892/ijo.2016.3698 PMid:27667556 DOI: https://doi.org/10.3892/ijo.2016.3698
Sato S, Genda T, Hirano K, Tsuzura H, Narita Y, Kanemitsu Y, et al. Up‐regulated aldo‐keto reductase family 1 member B10 in chronic hepatitis C: Association with serum alpha‐fetoprotein and hepatocellular carcinoma. Liver Int. 2012;32(9):1382-90. http://doi.org/10.1111/j.1478-3231.2012.02827.x PMid:22681639 DOI: https://doi.org/10.1111/j.1478-3231.2012.02827.x
El Moety HA, Maharem DA, Gomaa SH. Serotonin: Is it a marker for the diagnosis of hepatocellular carcinoma in cirrhotic patients? Alexandria J Med. 2013;49(4):369-78. DOI: https://doi.org/10.1016/j.ajme.2013.03.010
Barton JC, Chen WP, Emond MJ, Phatak PD, Subramaniam VN, Adams PC, et al. D519G is independently associated with markedly increased iron stores in HFE p. C282Y homozygotes. Blood Cells Mol Dis. 2017;63:15-20. http://doi.org/10.1016/j.bcmd.2016.11.009 PMid:27936396 DOI: https://doi.org/10.1016/j.bcmd.2016.11.009
Mori M, Genda T, Ichida T, Murata A, Kamei M, Tsuzura H, et al. Aldo‐keto reductase family 1 member B10 is associated with hepatitis B virus‐related hepatocellular carcinoma risk. Hepatol Res. 2017;47(3):E85-93. http://doi.org/10.1111/hepr.12725 PMid:27084455 DOI: https://doi.org/10.1111/hepr.12725
Hsu YC, Wu CY, Lane HY, Chang CY, Tai CM, Tseng CH, et al. Determinants of hepatocellular carcinoma in cirrhotic patients treated with nucleos (t) ide analogues for chronic hepatitis B. J Antimicrob Chemother. 2014;69(7):1920-7. http://doi.org/10.1093/jac/dku041 PMid:24576950 DOI: https://doi.org/10.1093/jac/dku041
Chen XL, Chen TW, Zhang XM, Li ZL, Zeng NL, Li T, et al. Quantitative assessment of the presence and severity of cirrhosis in patients with hepatitis B using right liver lobe volume and spleen size measured at magnetic resonance imaging. PLoS One. 2014;9(3):e89973. http://doi.org/10.1371/journal.pone.0089973 PMid:24594920 DOI: https://doi.org/10.1371/journal.pone.0089973
Kashani A, Salehi B, Anghesom D, Kawayeh AM, Rouse GA, Runyon BA. Spleen size in cirrhosis of different etiologies. J Ultrasound Med. 2015;34(2):233-8. http://doi.org/10.7863/ultra.34.2.233 PMid:25614396 DOI: https://doi.org/10.7863/ultra.34.2.233
Tsushima Y, Endo K. Spleen enlargement in patients with nonalcoholic fatty liver. Digest Dis Sci. 2000;45(1):196-200. http://doi.org/10.1023/a:1005446418589 PMid:10695635 DOI: https://doi.org/10.1023/A:1005446418589
Murata Y, Abe M, Hiasa Y, Azemoto N, Kumagi T, Furukawa S, et al. Liver/spleen volume ratio as a predictor of prognosis in primary biliary cirrhosis. J Gastroenterol. 2008;43(8):632-6. http://doi.org/10.1007/s00535-008-2202-9 PMid:18709486 DOI: https://doi.org/10.1007/s00535-008-2202-9
McCormick PA, Walker S, Benepal R. Hypersplenism is related to age of onset of liver disease. Ir J Med Sci. 2007;176(4):293-6. http://doi.org/10.1007/s11845-007-0089-8 PMid:17943410 DOI: https://doi.org/10.1007/s11845-007-0089-8
Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: Incidence and risk factors. Gastroenterology. 2004;127(5):S35-50. http://doi.org/10.1053/j.gastro.2004.09.014 PMid:15508101 DOI: https://doi.org/10.1053/j.gastro.2004.09.014
Bolondi L, Sofia S, Siringo S, Gaiani S, Casali A, Zironi G, et al. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: A cost effectiveness analysis. Gut. 2001;48(2):251-9. http://doi.org/10.1136/gut.48.2.251 PMid:11156649 DOI: https://doi.org/10.1136/gut.48.2.251
Tsai JF, Jeng JE, Ho MS, Chang WY, Hsieh MY, Lin ZY, et al. Effect of hepatitis C and B virus infection on risk of hepatocellular carcinoma: A prospective study. Br J Cancer. 1997;76(7):968-74. http://doi.org/10.1038/bjc.1997.493 PMid:9328161 DOI: https://doi.org/10.1038/bjc.1997.493
Matkowskyj KA, Bai H, Liao J, Zhang W, Li H, Rao S, et al. Aldoketoreductase family 1B10 (AKR1B10) as a biomarker to distinguish hepatocellular carcinoma from benign liver lesions. Hum Pathol. 2014;45(4):834-43. http://doi.org/10.1016/j.humpath.2013.12.002 PMid:24656094 DOI: https://doi.org/10.1016/j.humpath.2013.12.002
Heringlake S, Hofdmann M, Fiebeler A, Manns MP, Schmiegel W, Tannapfel A. Identification and expression analysis of the aldo-ketoreductase1-B10 gene in primary malignant liver tumours. J Hepatol. 2010;52(2):220-7. DOI: https://doi.org/10.1016/j.jhep.2009.11.005
Schmitz KJ, Sotiropoulos GC, Baba HA, Schmid KW, Müller D, Paul A, et al. AKR1B10 expression is associated with less aggressive hepatocellular carcinoma: A clinicopathological study of 168 cases. Liver Int. 2011;31(6):810-6. http://doi.org/10.1111/j.1478-3231.2011.02511.x PMid:21645211 DOI: https://doi.org/10.1111/j.1478-3231.2011.02511.x
Tsuzura H, Genda T, Sato S, Murata A, Kanemitsu Y, Narita Y, et al. Expression of aldo-keto reductase family 1member b10 in the early stages of human hepatocarcinogenesis. Int J Mol Sci. 2014;15(4):6556-68. http://doi.org/10.3390/ijms15046556 PMid:24747592 DOI: https://doi.org/10.3390/ijms15046556
Friemel J, Rechsteiner M, Frick L, Böhm F, Struckmann K, Egger M, et al. Intratumor heterogeneity in hepatocellular carcinoma. Clin Cancer Res. 2015;21(8):1951-61. http://doi.org/10.1158/1078-0432.CCR-14-0122 PMid:25248380 DOI: https://doi.org/10.1158/1078-0432.CCR-14-0122
Jin J, Liao W, Yao W, Zhu R, Li Y, He S. Aldo-keto reductase family 1 member B 10 mediates liver cancer cell proliferation through sphingosine-1-phosphate. Sci Rep. 2016;6:22746. http://doi.org/10.1038/srep22746 PMid:26948042 DOI: https://doi.org/10.1038/srep22746
Ye X, Li C, Zu X, Lin M, Liu Q, Liu J, et al. a large-scale multicenter study validates aldo-keto reductase family 1 member B10 as a prevalent serum marker for detection of hepatocellular carcinoma. Hepatology. 2019;69(6):2489-501. http://doi.org/10.1002/hep.30519 PMid:30672601 DOI: https://doi.org/10.1002/hep.30519
Kanno M, Kawaguchi K, Honda M, Horii R, Takatori H, Shimakami T, et al. Serum aldo-keto reductase family 1 member B10 predicts advanced liver fibrosis and fatal complications of nonalcoholic steatohepatitis. J Gastroenterol. 2019;54(6):549-57. http://doi.org/10.1007/s00535-019-01551-3 PMid:30707282 DOI: https://doi.org/10.1007/s00535-019-01551-3
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2022 Abdel-Naser Abdel-Atty Gadallah, Ehab Ahmed Abdel Atti, Tary Abdel Hamid Salman, Abd elSamie Othman Hassan, Hanan M. Bedair (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
http://creativecommons.org/licenses/by-nc/4.0
